Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Official Title

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

Eligibility Criteria

Ages Eligible for Study: 18 Years to 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Y. Joyce Liao, MD, PhD
Y. Joyce Liao, MD, PhD
Associate Professor of Ophthalmology and of Neurology at the Stanford University Medical Center
Jeffrey Dunn, MD
Jeffrey Dunn, MD
Multiple sclerosis specialist
Clinical Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


Angela Campbell
(650) 721-6188